149 related articles for article (PubMed ID: 34962955)
21. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
22. Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase.
Huang DQ; Li X; Le MH; Le AK; Yeo YH; Trinh HN; Zhang J; Li J; Wong C; Wong C; Cheung RC; Yang HI; Nguyen MH
Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1803-1812.e5. PubMed ID: 33465482
[TBL] [Abstract][Full Text] [Related]
23. Profile and value of FIB-4 in patients with dual chronic hepatitis C and B.
Liu CJ; Tseng TC; Yang WT; Su TH; Yang HC; Liu CH; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2019 Feb; 34(2):410-417. PubMed ID: 30151861
[TBL] [Abstract][Full Text] [Related]
24. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients.
Sou FM; Hu TH; Hung CH; Lai HC; Wang JH; Lu SN; Peng CY; Chen CH
Hepatol Int; 2020 Jul; 14(4):513-520. PubMed ID: 32319045
[TBL] [Abstract][Full Text] [Related]
25. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load.
Tseng TC; Liu CJ; Hsu CY; Hong CM; Su TH; Yang WT; Chen CL; Yang HC; Huang YT; Fang-Tzu Kuo S; Liu CH; Chen PJ; Chen DS; Kao JH
Gastroenterology; 2019 Dec; 157(6):1518-1529.e3. PubMed ID: 31470004
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B.
Jun CH; Hong HJ; Chung MW; Park SY; Cho SB; Park CH; Joo YE; Kim HS; Choi SK; Rew JS
World J Gastroenterol; 2013 Oct; 19(40):6834-41. PubMed ID: 24187458
[TBL] [Abstract][Full Text] [Related]
27. Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis.
Shin SH; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Kim BK
Liver Int; 2015 Mar; 35(3):1054-62. PubMed ID: 24930484
[TBL] [Abstract][Full Text] [Related]
28. Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients.
Liu J; Hu HH; Lee MH; Korenaga M; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; Mizokami M; Chen CJ; Yang HI
Sci Rep; 2017 Oct; 7(1):14352. PubMed ID: 29085039
[TBL] [Abstract][Full Text] [Related]
29. Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma.
Tseng TC; Liu CJ; Su TH; Yang WT; Chen CL; Yang HC; Wang CC; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
Am J Gastroenterol; 2017 Oct; 112(10):1564-1574. PubMed ID: 28853728
[TBL] [Abstract][Full Text] [Related]
30. Gamma-glutamyl transpeptidase-to-platelet ratio is an independent predictor of hepatitis B virus-related liver cancer.
Park YE; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Han S; Jeon MY; Heo JY; Song K; Kim SU
J Gastroenterol Hepatol; 2017 Jun; 32(6):1221-1229. PubMed ID: 27859587
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
[TBL] [Abstract][Full Text] [Related]
32. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients.
Mak LY; To WP; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
World J Gastroenterol; 2019 Mar; 25(11):1398-1408. PubMed ID: 30918432
[TBL] [Abstract][Full Text] [Related]
33. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.
Rodríguez-Díaz JL; Rosas-Camargo V; Vega-Vega O; Morales-Espinosa D; Mendez-Reguera A; Martínez-Tlahuel JL; Gamboa-Domínguez A; Arrieta O
Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):197-203. PubMed ID: 17359907
[TBL] [Abstract][Full Text] [Related]
34. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.
Lee HW; Kim SU; Park JY; Baatarkhuu O; Kim DY; Ahn SH; Han KH; Kim BK
Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725
[TBL] [Abstract][Full Text] [Related]
35. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis.
Ju YC; Jun DW; Choi J; Saeed WK; Lee HY; Oh HW
World J Gastroenterol; 2018 Oct; 24(40):4606-4614. PubMed ID: 30386110
[TBL] [Abstract][Full Text] [Related]
36. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B.
Lee J; Yoo SH; Sohn W; Kim HW; Choi YS; Won JH; Heo JY; Park SJ; Park YM
Clin Mol Hepatol; 2016 Sep; 22(3):339-349. PubMed ID: 27729627
[TBL] [Abstract][Full Text] [Related]
37. Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis.
Shin SK; Yim HJ; Kim JH; Lee CU; Yeon JE; Suh SJ; Jung YK; Kim YS; Kim JH; Kwon OS
Gut Liver; 2021 May; 15(3):430-439. PubMed ID: 33115966
[TBL] [Abstract][Full Text] [Related]
38. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
Kim GA; Han S; Kim HD; An J; Lim YS
J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
[TBL] [Abstract][Full Text] [Related]
39. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
[TBL] [Abstract][Full Text] [Related]
40. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]